[144] Editas Medicine, Inc. SEC Filing

Rhea-AI Filing Summary

Editas Medicine (EDIT) submitted a Form 144 disclosing a proposed sale of 800 shares of common stock with an aggregate market value of $2,184, listed for sale on Nasdaq and dated approximately 09/03/2025. The securities were acquired on 09/02/2025 through restricted stock unit vesting (1,550 shares acquired) and payment was in the form of equity compensation. The filing also reports two prior sales by the same person in the past three months: 726 shares on 06/03/2025 ($1,251.84) and 5,121 shares on 07/31/2025 ($12,756.92). The form includes the standard attestation that the seller is unaware of undisclosed material adverse information.

Positive

• Disclosure compliance: The filer provided a Rule 144 notice and reported prior sales, supporting transparency.
• Transaction source disclosed: Securities were acquired via Restricted Stock Unit vesting on 09/02/2025, with nature of payment noted as Equity Compensation.

Negative

• Insider sale proposed: The filing notifies a proposed disposition of 800 shares, which could be perceived negatively by some investors.
• Recent selling activity: The same seller reported two sales in the past three months totaling 5,847 shares (726 + 5,121), indicating ongoing monetization of holdings.

Insights

Financial Analyst

TL;DR: Small, routine insider sale after RSU vesting; limited market impact based on disclosed quantities.

The filing shows a proposed sale of 800 shares following a RSU vesting event that delivered 1,550 shares on 09/02/2025. Prior sales of 726 and 5,121 shares over the past three months are disclosed with gross proceeds. These are direct facts from the Form 144 and indicate monetization of equity compensation rather than an explicit corporate event or financing action. Absent additional context on total insider holdings or company market capitalization, this filing by itself appears to be a routine reporting of insider sales under Rule 144.

Corporate Governance Expert

TL;DR: The Form 144 is a standard compliance filing signaling insider disposition of vested equity.

The document documents compliance with Rule 144 for a proposed sale and includes the seller's representation about material non-public information and the Rule 10b5-1 notice fields (blank here). Reporting prior sales in the three-month window strengthens disclosure clarity. From a governance perspective, the form meets disclosure obligations; it does not by itself indicate governance failures or unusual insider behavior beyond routine monetization of compensation.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	E Trade Financial Corporation 3 Edison Financial Corporation Alphareta GA 30005	800	2184.00	89920164	09/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/02/2025	Restricted Stock Unit Vesting	Issuer			1550	09/02/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Linda C. Burkly 11 Hurley Street Cambridge MA 02141	Common Stock	06/03/2025	726	1251.84
Linda C. Burkly 11 Hurley Street Cambridge MA 02141	Common Stock	07/31/2025	5121	12756.92

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for EDIT disclose?

The Form 144 discloses a proposed sale of 800 shares of Editas Medicine common stock with an aggregate market value of $2,184, and prior sales of 726 and 5,121 shares in June and July 2025.

When were the shares being sold acquired?

The shares were acquired on 09/02/2025 via Restricted Stock Unit vesting, with 1,550 shares recorded as acquired on that date.

What form of payment was used for the acquired securities?

The filing states the nature of payment was Equity Compensation for the RSU vesting on 09/02/2025.

Were prior sales by the same person reported?

Yes. The filer reported sales of 726 shares on 06/03/2025 (gross proceeds $1,251.84) and 5,121 shares on 07/31/2025 (gross proceeds $12,756.92).

Does the filing state any material non-public information?

By signing, the person represents they do not know any material adverse non-public information regarding the issuer; no undisclosed material information is reported in the form.